MANAGEMENT OF ENDOCRINE DISEASE: Novel anabolic treatments for osteoporosis.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  European Journal of Endocrinology

• Publication date

  2018-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1530/EJE-17-0920PMID 29113980PMCID PMC5819362
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis

  2017cited by this paper
• Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial

  2017cited by this paper
• Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone Mass

  2017cited by this paper
• Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial.

  2017cited by this paper
• The Effect of Abaloparatide‐SC on Fracture Risk Is Independent of Baseline FRAX Fracture Probability: A Post Hoc Analysis of the ACTIVE Study

  2017cited by this paper
• Parathyroid hormone inhibits Notch signaling in osteoblasts and osteocytes.

  2017cited by this paper
• Greater Gains in Spine and Hip Strength for Romosozumab Compared With Teriparatide in Postmenopausal Women With Low Bone Mass

  2017cited by this paper
• One Year of Abaloparatide, a Selective Activator of the PTH1 Receptor, Increased Bone Formation and Bone Mass in Osteopenic Ovariectomized Rats Without Increasing Bone Resorption

  2017cited by this paper
• Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: The ACTIVE phase 3 trial.

  2017cited by this paper
• Romosozumab - Promising or Practice Changing?

  2017cited by this paper
• Abaloparatide: First Global Approval

  2017cited by this paper
• Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1–34)

  2017cited by this paper
• Romosozumab Treatment in Postmenopausal Women with Osteoporosis.

  2016cited by this paper
• Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.

  2016cited by this paper
• Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling.

  2016cited by this paper
• Carcinogenicity risk assessment of romosozumab: A review of scientific weight-of-evidence and findings in a rat lifetime pharmacology study.

  2016cited by this paper
• Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.

  2015cited by this paper
• Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.

  2015cited by this paper
• Romosozumab in postmenopausal women with low bone mineral density

  2014cited by this paper
• Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.

  2014cited by this paper
• Effects of PTH on osteocyte function.

  2013cited by this paper
• Changes in bone sclerostin levels in mice after ovariectomy vary independently of changes in serum sclerostin levels

  2013cited by this paper
• Serum sclerostin levels in men with idiopathic osteoporosis.

  2013cited by this paper
• Novel SOST gene mutation in a sclerosteosis patient and her parents.

  2013cited by this paper
• Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches

  2013cited by this paper
• Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial.

  2013cited by this paper
• The osteocyte: an endocrine cell ... and more.

  2013cited by this paper
• Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading.

  2012cited by this paper
• Update on Wnt signaling in bone cell biology and bone disease.

  2012cited by this paper
• Targeted deletion of Sost distal enhancer increases bone formation and bone mass

  2012cited by this paper
• TREM2 and β-Catenin Regulate Bone Homeostasis by Controlling the Rate of Osteoclastogenesis

  2012cited by this paper
• Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1–34)] in postmenopausal osteoporosis

  2011cited by this paper
• Determinants of serum sclerostin in healthy pre‐ and postmenopausal women

  2011cited by this paper
• Single‐dose, placebo‐controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

  2011cited by this paper
• Biphasic and Dosage-Dependent Regulation of Osteoclastogenesis by β-Catenin

  2011cited by this paper
• Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women.

  2010cited by this paper
• Osteocyte Wnt/β-Catenin Signaling Is Required for Normal Bone Homeostasis

  2010cited by this paper
• Update in new anabolic therapies for osteoporosis.

  2010cited by this paper
• First missense mutation in the SOST gene causing sclerosteosis by loss of sclerostin function

  2010cited by this paper
• Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength

  2010cited by this paper
• Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose.

  2010cited by this paper
• Serum IGF‐1 Determines Skeletal Strength by Regulating Subperiosteal Expansion and Trait Interactions

  2009cited by this paper
• Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis

  2009cited by this paper
• Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice.

  2009cited by this paper
• Targeted Deletion of the Sclerostin Gene in Mice Results in Increased Bone Formation and Bone Strength

  2008cited by this paper
• Growth hormone, insulin-like growth factors, and the skeleton.

  2008cited by this paper
• Where Wnts Went: The Exploding Field of Lrp5 and Lrp6 Signaling in Bone

  2008cited by this paper
• Wnt signaling: a win for bone.

  2008cited by this paper
• Mechanical Stimulation of Bone in Vivo Reduces Osteocyte Expression of Sost/Sclerostin*

  2008cited by this paper
• Teriparatide or alendronate in glucocorticoid-induced osteoporosis.

  2007cited by this paper
• Anorexia nervosa and osteoporosis

  2007cited by this paper
• Structure-based mutation analysis shows the importance of LRP5 beta-propeller 1 in modulating Dkk1-mediated inhibition of Wnt signaling.

  2007cited by this paper
• Bone morphogenetic proteins and their antagonists

  2007cited by this paper
• The genetics of low-density lipoprotein receptor-related protein 5 in bone: a story of extremes.

  2007cited by this paper
• Molecular and cellular mechanisms of the anabolic effect of intermittent PTH.

  2007cited by this paper
• Wnt/β-Catenin Signaling Is a Normal Physiological Response to Mechanical Loading in Bone*

  2006cited by this paper
• Osteosarcoma and Teriparatide?

  2006cited by this paper
• Wnt/beta-catenin signaling in development and disease.

  2006cited by this paper
• Defining a Noncarcinogenic Dose of Recombinant Human Parathyroid Hormone 1–84 in a 2-Year Study in Fischer 344 Rats

  2006cited by this paper
• Increased Prevalence of Radiological Spinal Deformities in Adult Patients With GH Deficiency: Influence of GH Replacement Therapy

  2006cited by this paper
• Role of IGF‐I Signaling in Regulating Osteoclastogenesis

  2006cited by this paper
• Regulation of bone mass by Wnt signaling.

  2006cited by this paper
• Bone Density Ligand, Sclerostin, Directly Interacts With LRP5 but Not LRP5G171V to Modulate Wnt Activity

  2006cited by this paper
• An estimate of the worldwide prevalence and disability associated with osteoporotic fractures

  2006cited by this paper
• LRP5 Mutations Linked to High Bone Mass Diseases Cause Reduced LRP5 Binding and Inhibition by SOST*

  2006cited by this paper
• Skeletal actions of insulin-like growth factors

  2006cited by this paper
• Initial experience with teriparatide in the United States*

  2006cited by this paper
• The Wnt Co-receptor LRP5 Is Essential for Skeletal Mechanotransduction but Not for the Anabolic Bone Response to Parathyroid Hormone Treatment*

  2006cited by this paper
• Sclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling*

  2005cited by this paper
• Systematic review and meta-analysis of strategies for the diagnosis of suspected pulmonary embolism

  2005cited by this paper
• Daily and cyclic parathyroid hormone in women receiving alendronate.

  2005cited by this paper
• Essential role of beta-catenin in postnatal bone acquisition.

  2005cited by this paper
• Current Guidelines for Adult GH Replacement

  2005cited by this paper
• Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease.

  2005cited by this paper
• Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation.

  2005cited by this paper
• TOPGAL Mice Show That the Canonical Wnt Signaling Pathway Is Active During Bone Development and Growth and Is Activated by Mechanical Loading In Vitro

  2005cited by this paper
• The fate of circulating osteoblasts.

  2005cited by this paper
• Canonical WNT Signaling Promotes Osteogenesis by Directly Stimulating Runx2 Gene Expression*

  2005cited by this paper
• Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis.

  2005cited by this paper
• Essential Role of β-Catenin in Postnatal Bone Acquisition*

  2005cited by this paper
• Differential Effects of Teriparatide on BMD After Treatment With Raloxifene or Alendronate

  2004cited by this paper
• Bone Neoplasms in F344 Rats Given Teriparatide [rhPTH(1-34)] Are Dependent on Duration of Treatment and Dose

  2004cited by this paper
• Sclerostin Is an Osteocyte-expressed Negative Regulator of Bone Formation, But Not a Classical BMP Antagonist

  2004cited by this paper
• Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation.

  2004cited by this paper
• Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density.

  2003cited by this paper
• The effects of parathyroid hormone, alendronate, or both in men with osteoporosis.

  2003cited by this paper
• Osteocyte control of bone formation via sclerostin, a novel BMP antagonist

  2003cited by this paper
• Sclerostin Is a Novel Secreted Osteoclast-derived Bone Morphogenetic Protein Antagonist with Unique Ligand Specificity*

  2003cited by this paper
• The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.

  2003cited by this paper
• Secreted antagonists of the Wnt signalling pathway

  2003cited by this paper
• High bone density due to a mutation in LDL-receptor-related protein 5.

  2002cited by this paper
• Control of -Catenin Phosphorylation/Degradation by a Dual-Kinase Mechanism

  2002cited by this paper
• Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease

  2002cited by this paper
• Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa.

  2002cited by this paper
• Osteoblast-specific Knockout of the Insulin-like Growth Factor (IGF) Receptor Gene Reveals an Essential Role of IGF Signaling in Bone Matrix Mineralization*

  2002cited by this paper
• Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism.

  2002cited by this paper
• The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation.

  2002cited by this paper
• A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait.

  2002cited by this paper
• Wnt Signaling Protects 3T3-L1 Preadipocytes from Apoptosis through Induction of Insulin-like Growth Factors*

  2002cited by this paper
• Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST).

  2001cited by this paper

• Impact of anti-osteoporosis medication on refracture prevention following osteoporotic vertebral fracture: a systematic review and meta-analysis

  2025cites this paper
• Anti-osteoporosis medication in patients with posterior spine fusion: a systematic review and meta-analysis.

  2025cites this paper
• Clinical Recommendations for the Perioperative Management of Biologic Medications for Nonrheumatologic Diseases in Total Joint Arthroplasty

  2025cites this paper
• Role of denosumab in lipid metabolism disorders: clinical significance and potential mechanisms

  2025cites this paper
• Differential expression of lncRNAs and mRNAs in bone marrow-derived mesenchymal stem cells under continuous and intermittent teriparatide treatment.

  2025cites this paper
• Controversial causal association between IGF family members and osteoporosis: a Mendelian randomization study between UK and FinnGen biobanks

  2024cites this paper
• Traditional Chinese medicine in osteoporosis: from pathogenesis to potential activity

  2024cites this paper
• Cementless Total Knee Arthroplasty: Is it Safe in Demineralized Bone?

  2024cites this paper
• OsteoMac: a new player on the bone biology scene.

  2024cites this paper
• PTH and the Regulation of Mesenchymal Cells within the Bone Marrow Niche

  2024cites this paper
• Transcriptome Sequencing Identifies Abnormal lncRNAs and mRNAs and Reveals Potentially Hub Immune-Related mRNA in Osteoporosis with Vertebral Fracture

  2024cites this paper
• Histological Assessment of the Effect of Teriparatide Treatment on Mandibular Bone Defect Healing in Rats

  2024cites this paper
• Surgical Management of Adult Spinal Deformity Patients with Osteoporosis

  2024cites this paper
• Successful treatment of adjunctive teriparatide therapy for medication-related osteonecrosis of the jaw: a report of two cases

  2024cites this paper
• RANK–RANKL–OPG Axis in MASLD: Current Evidence Linking Bone and Liver Diseases and Future Perspectives

  2024cites this paper
• Personalized Approaches to Spine Surgery

  2024cites this paper
• Mechanistic Insights and Therapeutic Strategies in Osteoporosis: A Comprehensive Review

  2024influential citation
• Clinical challenges and considerations in pharmacotherapy of osteoporosis due to menopause

  2024cites this paper
• Enhancement of Local Osseointegration and Implant Stability of Titanium Implant in Osteoporotic Rats by Biomimetic Multilayered Structures Containing Catalpol

  2024influential citation
• The Impacts of Teriparatide Treatment on Bone Alkaline Phosphatase, Calcium and Phosphate Serum Levels in Rats

  2023cites this paper
• Relative comparison of chronic kidney disease-mineral and bone disorder rat models

  2023cites this paper
• Bioactivity, Molecular Mechanism, and Targeted Delivery of Flavonoids for Bone Loss

  2023cites this paper
• The Portuguese state of the art on osteoporosis and fracture risk: an update on the treatment options

  2023cites this paper
• Toxoplasma gondii excretory/secretory proteins promotes osteogenic differentiation of bone marrow mesenchymal stem cells via aerobic glycolysis mediated by Wnt/β-catenin signaling pathway

  2023cites this paper
• Role of nanotechnology in the prolonged release of drugs by the subcutaneous route

  2023cites this paper
• Osteoporosis – a partially recognized challenge for oncology

  2023cites this paper
• The role of insulin-like growth factor-1 in bone remodeling: A review.

  2023cites this paper
• Osteoporosis in COPD patients: Risk factors and pulmonary rehabilitation

  2022cites this paper
• Medical optimization of osteoporosis for adult spinal deformity surgery: a state-of-the-art evidence-based review of current pharmacotherapy

  2022cites this paper
• Transdermal formulations and strategies for the treatment of osteoporosis

  2022cites this paper
• Skeletal disorders associated with the growth hormone–insulin-like growth factor 1 axis

  2022cites this paper
• LGR5 enhances the osteoblastic differentiation of MC3T3-E1 cells through the Wnt/β-catenin pathway

  2021cites this paper
• Combining sclerostin neutralization with tissue engineering: an improved strategy for craniofacial bone repair.

  2021cites this paper
• Osteoporosis therapies and their mechanisms of action (Review)

  2021cites this paper
• Growth Hormone As Antiaging Factor in Old Bones

  2021influential citation
• The Osteocyte: From “Prisoner” to “Orchestrator”

  2021cites this paper
• Effect of resveratrol and mesenchymal stem cell monotherapy and combined treatment in management of osteoporosis in ovariectomized rats: Role of SIRT1/FOXO3a and Wnt/β-catenin pathways.

  2021cites this paper
• Yukmijihwang-Tang Suppresses Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL)-Induced Osteoclast Differentiation and Prevents Ovariectomy (OVX)-Mediated Bone Loss

  2021cites this paper
• Syndecan‐3 enhances anabolic bone formation through WNT signaling

  2021cites this paper
• Teriparatide (recombinant human parathyroid hormone 1‐34) therapy in myeloma patients with severe osteoporosis and fractures despite effective anti‐myeloma therapy and bisphosphonates: A pilot study

  2020cites this paper
• Preactivation of β‐catenin in osteoblasts improves the osteoanabolic effect of PTH in type 1 diabetic mice

  2020cites this paper
• Pharmacologic basis of sclerostin inhibition

  2020cites this paper
• Pharmacological interventions targeting bone diseases in adjunction with bone grafting

  2020cites this paper
• Conditional deletion of Adrb2 in mesenchymal stem cells attenuates osteoarthritis-like defects in temporomandibular joint.

  2020cites this paper
• Network and pathway-based analyses of genes associated with osteoporosis

  2020cites this paper
• Study of the combined effects of PTH treatment and mechanical loading in postmenopausal osteoporosis using a new mechanistic PK-PD model

  2020cites this paper
• Safety of Romosozumab in Osteoporotic Men and Postmenopausal Women: A Meta-Analysis and Systematic Review

  2020cites this paper
• Future Treatment Strategies

  2020cites this paper
• Catalpol Promotes the Proliferation and Differentiation of Osteoblasts Induced by High Glucose by Inhibiting KDM7A

  2020cites this paper
• Pharmacological Therapy of Osteoporosis: What’s New?

  2020cites this paper
• Pharmacological Therapy of Osteoporosis: What ’ s New?

  2020influential citation
• Wnt Signaling in Cartilage Development

  2020cites this paper
• Sclerostin regulation: a promising therapy for periodontitis by modulating alveolar bone

  2020cites this paper
• MANAGEMENT OF ENDOCRINE DISEASE: Male osteoporosis: diagnosis and management. Should the treatment and target be the same as for female osteoporosis?

  2020cites this paper
• Extremely elevated serum alkaline phosphatase level upon treatment with teriparatide: a case report

  2020cites this paper
• Challenges in preventing bone loss induced by aromatase inhibitors.

  2020cites this paper
• Romosozumab: A first-in-class sclerostin inhibitor for osteoporosis.

  2020cites this paper
• Bisphosphonates and parathyroid hormone analogs for improving bone quality in spinal fusion: State of evidence

  2020cites this paper
• The expression and regulation of Wnt1 in tooth movement-initiated mechanotransduction.

  2020cites this paper
• Parathyroid hormone increases alveolar bone homoeostasis during orthodontic tooth movement in rats with periodontitis via crosstalk between STAT3 and β-catenin

  2020cites this paper
• Catalpol Promotes the Proliferation and Differentiation of Osteoblasts Induced by High Glucose by Inhibiting KDM7A Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

  2020cites this paper
• Catalpol Promotes the Proliferation and Differentiation of Osteoblasts Induced by High Glucose by Inhibiting KDM7A Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

  2020cites this paper
• Biophysical Regulation of Stem Cell Osteogenic Lineage Commitment: A Role for the Cytoskeleton

  2019influential citation
• RIPK1 suppresses apoptosis mediated by TNF and caspase-3 in intervertebral discs

  2019cites this paper
• Arbutin promotes MC3T3-E1 mouse osteoblast precursor cell proliferation and differentiation via the Wnt/β-catenin signaling pathway

  2019cites this paper
• MSC contributions to loading-induced bone formation: a role for adenylyl cyclase 6

  2019cites this paper
• Wnt Antagonists in Hematopoietic and Immune Cell Fate: Implications for Osteoporosis Therapies

  2019cites this paper
• Gene co-expression network analysis identifies BRCC3 as a key regulator in osteogenic differentiation of osteoblasts through a β-catenin signaling dependent pathway

  2019cites this paper
• Interaction among Calcium Diet Content, PTH (1-34) Treatment and Balance of Bone Homeostasis in Rat Model: The Trabecular Bone as Keystone

  2019cites this paper
• Catalpol promotes the osteogenic differentiation of bone marrow mesenchymal stem cells via the Wnt/β-catenin pathway

  2019influential citation
• Novel actions of sclerostin on bone.

  2019cites this paper
• Syndecan-3 enhances anabolic bone formation through WNT signalling

  2019cites this paper
• The osteocyte: a multifunctional cell within the bone.

  2019cites this paper
• Effects of locally applied Insulin-like Growth Factor-I on osseointegration

  2019cites this paper
• Anabolic Agents for the Treatment of Postmenopausal Osteoporosis

  2019cites this paper
• Secondary fracture prevention: Drug treatment, fall prevention and nutrition requirements.

  2019cites this paper
• Prospect of circular RNA in osteogenesis: A novel orchestrator of signaling pathways

  2019cites this paper
• Increased serum sclerostin levels in patients with active acromegaly.

  2019cites this paper
• Novel actions of sclerostin on bone

  2018cites this paper
• Novel actions of sclerostin on bone

  2018cites this paper
• Novel actions of sclerostin on bone

  2018cites this paper
• Novel actions of sclerostin on bone

  2018cites this paper
• Novel actions of sclerostin on bone

  2018cites this paper
• Novel actions of sclerostin on bone

  2018cites this paper
• Peptide TQS169 prevents osteoporosis in rats by enhancing osteogenic differentiation and calcium absorption

  2018cites this paper
• Levels of serum sclerostin, FGF-23, and intact parathyroid hormone in postmenopausal women treated with calcitriol

  2018cites this paper
• Parathyroid hormone independent hypercalcemia in adults.

  2018cites this paper
• Dynamic expression of SMAD3 is critical in osteoblast differentiation of PDMCs.

  2018cites this paper
• MECHANISMS IN ENDOCRINOLOGY: Bone Marrow Adiposity and bone, a bad romance?

  2018cites this paper
• Analysis of Circulating Mediators of Bone Remodeling in Prader–Willi Syndrome

  2018influential citation
• Pituitary Diseases and Bone

  2018cites this paper
• Romosozumab treatment in postmenopausal women with osteoporosis: a meta-analysis of randomized controlled trials

  2018cites this paper
• Gaucher disease iPSC-derived osteoblasts have developmental and lysosomal defects that impair bone matrix deposition

  2018cites this paper
• levels of serum sclerostin, FgF-23, and intact parathyroid hormone in postmenopausal women treated with calcitriol

  2018cites this paper
• levels of serum sclerostin, FgF-23, and intact parathyroid hormone in postmenopausal women treated with calcitriol

  2018cites this paper
• levels of serum sclerostin, FgF-23, and intact parathyroid hormone in postmenopausal women treated with calcitriol

  2018cites this paper
• Dietary nutraceuticals as backbone for bone health.

  2018cites this paper
• Novel actions of sclerostin on bone

  2018cites this paper
• Novel actions of sclerostin on bone

  2018cites this paper
• Novel actions of sclerostin on bone

  2018cites this paper